Treatment of Acne Scarring With a Novel Procedure Combination

Acne Scarring Clinical Trial

Official title:

The Effect of Subcision and Calcium Hydroxylapatite (Radiesse) Injection on Rolling Acne Scarring Appearance

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00510055
• Other study ID #: STU752
• Status: Completed
• Phase: N/A
• Start date: June 2007
• Est. completion date: July 2009

Study information

• Verified date: November 2021
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to look at the efficacy of subdermal manipulation and filler injection in the improvement of acne scar appearance.

Description:

The primary objective of this study is to determine whether the use of subcision in conjunction with calcium hydroxylapatite injections will improve the appearance of rolling acne scars better than subcision alone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 2009
• Est. primary completion date: July 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 and over
• Have two acne scar areas
• The subjects are in good health
• The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator.

Exclusion Criteria:

• Under 18 years of age
• Pregnancy or Lactation
• Subjects who are unable to understand the protocol or to give informed consent
• Subjects with mental illness

Related Conditions & MeSH terms

• Acne Scarring
• Cicatrix

Intervention

Procedure:
• subdermal manipulation ONLY
scars receive subdermal manipulation ONLY
• subdermal manipulation AND injection of a filler
scars receive subdermal manipulation AND injection of a filler

Locations

Country	Name	City	State
United States	Northwestern University Feinberg School of Medicine, Department of Dermatology	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Scar Improvement		3.5 months
Secondary	Adverse Events		3.5 months